Kunal Malik

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Emma Guttman‐Yassky, Patrick M. Brunner, Avidan U. Neumann et al. · Journal of the American Academy of Dermatology · 2018 · 328 citations · Full text

The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins

Patrick M. Brunner, Mayte Suárez‐Fariñas, Helen He et al. · Scientific Reports · 2017 · 255 citations · Full text

Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab

Patrick M. Brunner, Ana B. Pavel, Saakshi Khattri et al. · Journal of Allergy and Clinical Immunology · 2018 · 188 citations · Full text

Inflammation, Allergy, Atopic Dermatitis +8

Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature

Kunal Malik, Helen He, Thy Huynh et al. · Journal of Allergy and Clinical Immunology · 2018 · 138 citations · Full text

Functional Genomics, Th17 Skewing, Medicine +12

Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis

Lisa Zhou, Alexandra Leonard, Ana B. Pavel et al. · Journal of Allergy and Clinical Immunology · 2019 · 134 citations · Full text

Molecular Phenotype, Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis +6